Skip to main content

Table 1 Parameter values used in the decision tree model and sensitivity analysis

From: Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies

Parameter Base case estimate Sensitivity range References
Epidemiologic
 Camp size [2015]
  Djibouti [destination from Somalia] 22,080 NA [10]
  Algeria [destination from Sahara] 90,000 NA [12]
  Mauritania [destination from Mali] 48,000 NA [11]
 Crude Birth Rate (births per 1000 per year) [2015]
  Somalia [country of origin] 44 NA [20]
  Western Sahara [region of origin] 20 NA [20]
  Mali [country of origin] 44 NA [20]
 Camp-based Birth cohort per year (Camp size x Crude Birth Rate)
  Djibouti 972 NA  
  Algeria 1800 NA  
  Mauritania 2112 NA  
 Average life expectancy [2015]
  Somalia [country of origin] 56 NA [29]
  Morocco [nearest to Western Sahara] 74 NA [29]
  Mali [country of origin] 58 NA [29]
 Population proportion who are HBsAg+
  Somalia 0.1477 0.1377–0.1584 (95% CI) [52]
  Morocco [substituted for Western Sahara] 0.0109 0.0105–0.0114 (95% CI) [52]
  Mali 0.1307 0.1269–0.1347 (95% CI) [52]
 Transmission rate
  Perinatal transmission in chronic infected mother 0.91 NA [24]
 Disease progression, %
  HBV carrier to chronic infection 0.073 0.003–0.073* [25]
  Chronic hepatitis B to HBV carrier 0.17 0.105–0.306 (Assumed max) [25]
  Chronic hepatitis B to compensated cirrhosis 0.129 0.004–0.153 [53]
  Chronic hepatitis B to hepatocellular carcinoma (HCC) 0.005 0.002–0.007 [25]
  Compensated cirrhosis to decompensated cirrhosis 0.054 0.028–0.1 [25]
  Compensated cirrhosis to HCC 0.03 0.01–0.1 [27]
Mortality rate
 Background mortality Country-specific tables   [28]
 Compensated cirrhosis 0.037 0.03–0.044 [53]
 Decompensated cirrhosis 1 0.9–1 (Assumed, − 10%) Assumed
 HCC 1 0.9–1 (Assumed, − 10%) [53]
Clinical interventions
 Vaccine coverage (Hepatitis B, 3 doses) [2015]    
  Djibouti 0.78 0.63–1 (− 25% to 1)* [15]
  Algeria 0.95 0.73–1 (− 25% to 1)* [15]
  Mauritania 0.73 0.55–1 (− 25% to 1)* [15]
 Vaccine protection, %
  Birth dose + Routine Immunization (RI) 0.953 0.946–0.960 (95% CI) [30]
 RI 0.722 0.676–.765 (95% CI) [30]
Residual Susceptibility in Immunologic Failure 0.05 0.0375–0.0625
(+/−  25%)
[34]
Economic [2015 USD]
 UNICEF price per dose 0.173 NA [54]
 Operational costs per dose or test 0.93 0.11–2.00* (Assumed max) [26, 44]
 Cost per rapid diagnostic test (RDT) 0.50 NA [55]
 Sensitivity of RDT (pooled) 0.948 0.946–0.960 [32]
 Specificity of RDT (pooled) 0.995 0.993–1 [32]
  1. *Sensitivity range used in Monte Carlo simulation
  2. Abbreviations: HBsAg hepatitis B virus surface antigen, HBV hepatitis B virus, HCC hepatocellular carcinoma, RDT rapid diagnostic test